Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s177, 2023. DOI: 10.25251/skin.7.supp.177. Disponível em: https://skin.dermsquared.com/skin/article/view/2002. Acesso em: 19 apr. 2025.